Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

被引：0
|
作者：
Couban, Stephen
Benevolo, Giulia
Donnellan, William
Cultrera, Jennifer
Koschmieder, Steffen
Verstovsek, Srdan
Hooper, Gregory
Hertig, Christian
Tandon, Maneesh
Dimier, Natalie
Templeton, Ian
Passamonti, Francesco
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4179
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial
    Harrison, Claire N.
    Clark, Richard E.
    Chacko, Joseph
    Knapper, Steven
    Yin, John
    Milojkovic, Dragana
    Farquharson, Mira
    Ali, Sabra
    Garg, Mamta K.
    Andrews, Christopher
    Csci, Cstat
    Graham, Susan M.
    Mead, Adam J.
    BLOOD, 2013, 122 (21)
  • [22] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study
    Rampal, Raajit K.
    Verstovsek, Srdan
    Devlin, Sean M.
    Stein, Eytan M.
    Kadia, Tapan M.
    Mauro, Michael J.
    Pemmaraju, Naveen
    Alvarez, Kelsey
    Ard, Nicole
    Goodman, Tawni
    Marek, Kelly
    Bose, Prithviraj
    BLOOD, 2018, 132
  • [23] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients With Myelofibrosis: Initial Results of a Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 8 - 10
  • [24] A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
    Daver, Naval
    Dao, Kim-Hien
    Assad, Albert
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S351 - S351
  • [25] Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study
    Passamonti, Francesco
    Gupta, Vikas
    Martino, Bruno
    Foltz, Lynda
    Zaritskey, Andrey
    Al-Ali, Haifa Kathrin
    Tavares, Renato
    Maffioli, Margherita
    Raanani, Pia
    Giraldo, Pilar
    Griesshammer, Martin
    Guglielmelli, Paola
    Bouard, Catherine
    Paley, Carole
    Tiwari, Ranjan
    Vannucchi, Alessandro M.
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) : 558 - 566
  • [26] Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
    Durrant, Simon T.
    Nagler, Arnon
    Guglielmelli, Paola
    Lavie, David
    le Coutre, Philipp
    Gisslinger, Heinz
    Chuah, Charles
    Maffioli, Margherita
    Bharathy, Savita
    Dong, Tuochuan
    Wroclawska, Monika
    Martinez Lopez, Joaquin
    HAEMATOLOGICA, 2019, 104 (12) : E551 - E554
  • [27] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
    Rampal, Raajit K.
    Verstovsek, Srdan
    Devlin, Sean M.
    King, Amber C.
    Stein, Eytan M.
    Pemmaraju, Naveen
    Mauro, Michael J.
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Alvarez, Kelsey
    Ard, Nicole
    Goodman, Tawni
    Taylor, Bria
    Bose, Prithviraj
    BLOOD, 2019, 134
  • [28] Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
    Gupta, Vikas
    Yacoub, Abdulraheem
    Verstovsek, Srdan
    Mesa, Ruben A.
    Harrison, Claire N.
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Deeg, H. Joachim
    Fazal, Salman
    Foltz, Lynda
    Mattison, Ryan J.
    Miller, Carole B.
    Parameswaran, Vinod
    Gharpure, Vishwanath
    Hernandez, Christopher
    Wang, Tianhua
    Talpaz, Moshe
    BLOOD, 2021, 138
  • [29] A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
    Heidel, Florian
    Ribrag, Vincent
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Hayat, Amjad
    Conneally, Eibhlin
    Kindler, Thomas
    Martino, Bruno
    Lipka, Daniel B.
    Acharyya, Suddhasatta
    Binlich, Florence
    Liu, Tracy
    Mu, Song
    Harrison, Claire N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.
    Oh, David Yoonsuk
    Kilari, Deepak
    Darr, Christopher
    Zarrabi, Kevin Kayvan
    Hawley, Jessica E.
    Pachynski, Russell Kent
    Tagawa, Scott T.
    Yang, Yuanquan
    Buetikofer, Simon
    Xia, Qing
    Von Amsberg, Gunhild
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS434 - TPS434
12345